Sensorion SA (ALSEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sensorion SA (ALSEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8258
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, acute vertigo, meniere’s disease, migraine-associated vertigo, benign paroxysmal positional vertigo, vestibular lesions and tinnitus, and ototoxicity. Sensorion offers clinical trial with SENS-111, a treatment against acute vertigo tested on volunteers to determine pharmacokinetics and tolerability; and SENS-401, a class drug to treat sudden sensori neural hearing loss. The company operates through researchers, clinicians and other partners, to develop its drugs. Sensorion is headquartered in Montpellier, France.

Sensorion SA (ALSEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sensorion SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sensorion SA, Medical Devices Deals, 2012 to YTD 2018 9
Sensorion SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sensorion SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sensorion Raises USD4.6 Million in Venture Financing 11
Partnerships 12
Sensorion Enters into Partnership Agreement with Cochlear 12
Palau Pharma Enters Into Agreement With Sensorion To Develop UR-63325 13
Equity Offering 14
Sensorion Raises USD10.2 Million in Private Placement of Shares 14
Sensorion Raises USD1.8 Million in Private Placement of Shares 16
Sensorion Raises USD8.7 Million in Private Placement of Shares 17
Sensorion Raises USD9 Million in IPO 18
Sensorion SA – Key Competitors 19
Sensorion SA – Key Employees 20
Sensorion SA – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Oct 18, 2018: Sensorion reports pipeline update and first-half-year 2018 results; re-design of SENS-111 study 22
Apr 12, 2018: Sensorion reports full year 2017 results 25
Oct 18, 2017: Sensorion Reports 2017 First-Half Results 27
Mar 14, 2017: Sensorion Reports Full Year 2016 Results in Line with Status of Clinical Development 30
Corporate Communications 32
May 22, 2018: Sensorion Appoints Professor Christine Petit, MD, PhD as Chair of its Scientific Advisory Board 32
Jun 08, 2017: Sensorion Announces Results from 2017 Annual General Meeting 33
Apr 13, 2017: SENSORION: Intensification of the Company’s International Development with the Appointment of a New CEO 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Sensorion SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sensorion SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sensorion SA, Deals By Therapy Area, 2012 to YTD 2018 8
Sensorion SA, Medical Devices Deals, 2012 to YTD 2018 9
Sensorion SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sensorion Raises USD4.6 Million in Venture Financing 11
Sensorion Enters into Partnership Agreement with Cochlear 12
Palau Pharma Enters Into Agreement With Sensorion To Develop UR-63325 13
Sensorion Raises USD10.2 Million in Private Placement of Shares 14
Sensorion Raises USD1.8 Million in Private Placement of Shares 16
Sensorion Raises USD8.7 Million in Private Placement of Shares 17
Sensorion Raises USD9 Million in IPO 18
Sensorion SA, Key Competitors 19
Sensorion SA, Key Employees 20

List of Figures
Sensorion SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sensorion SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sensorion SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sensorion SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sensorion SA (ALSEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genesis Healthcare, Inc.:企業の戦略・SWOT・財務情報
    Genesis Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report Summary Genesis Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tokuyama Corp (4043):企業の財務・戦略的SWOT分析
    Tokuyama Corp (4043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Empyrean Energy PLC (EME):企業の財務・戦略的SWOT分析
    Summary Empyrean Energy PLC (Empyrean Energy) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company's projects include China Block 29/11 project, Duyung PSC project, and Sacramento Basin Projects. Its Duyung PSC project covers a …
  • Rocky Brands Inc (RCKY):企業の財務・戦略的SWOT分析
    Rocky Brands Inc (RCKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Nexus AG (NXU):企業の財務・戦略的SWOT分析
    Summary Nexus AG (Nexus) is a healthcare technology company that provides healthcare software solutions. The company provides products such as NEXUS and HIS, a hospital information system; NEXUS and DIS, a special ward and department solutions; and NEXUS and QM, a solution in quality management, amo …
  • GATC Biotech AG-製薬・医療分野:企業M&A・提携分析
    Summary GATC Biotech AG (GATC Biotech) is a healthcare service center that offers sequencing services. The center products category include nextgen, liquid biopsy, tissue biopsy, sanger and cell culture. It offers nextgen products such as inview transcriptome, inview metagenome, inview microbiome, i …
  • Netcare Ltd (NTC):企業の財務・戦略的SWOT分析
    Summary Netcare Ltd (Netcare) is a healthcare service provider that offers patient care services. The center provides medical facilities and treatments in the fields of breast care, oncology, orthopedics, renal care, transplants and weight management. Its facilities include medicross centers, netcar …
  • Komax Holding AG (KOMN):企業の財務・戦略的SWOT分析
    Komax Holding AG (KOMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Vior Inc (VIO):企業の財務・戦略的SWOT分析
    Summary Vior Inc (Vior) is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of gold and silver metal properties in North and Latin America. Its projects comprise Mosseau Gold project, Foothills Rutile project, Vezza-Noyard Go …
  • Moldex-Metric Inc:企業の戦略的SWOT分析
    Moldex-Metric Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Portola Pharmaceuticals Inc (PTLA):製薬・医療:M&Aディール及び事業提携情報
    Summary Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inh …
  • Concordia International Rx UK Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Rx UK Ltd (Concordia International), formerly Amdipharm Mercury Company Ltd, a subsidiary of Concordia International Corp, is a manufacturer of pharmaceutical products and orphan drugs. The company’s products include acetazolamide, adenosine, adrenaline acid tartrate, …
  • PORR AG (POS):企業の財務・戦略的SWOT分析
    PORR AG (POS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Lombard Odier Private Clients:企業の戦略・SWOT・財務情報
    Lombard Odier Private Clients - Strategy, SWOT and Corporate Finance Report Summary Lombard Odier Private Clients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Open Text Corporation (OTEX):企業の財務・戦略的SWOT分析
    Open Text Corporation (OTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Orsted AS (DENERG)-エネルギー分野:企業M&A・提携分析
    Summary Orsted AS (Orsted) formerly Dong Energy A/S is an integrated energy company that procures, produces, distributes and trades energy and energy related products. It generates electricity and heat using conventional fuel and wind energy sources. The company also develops, constructs, owns and o …
  • Cosan S.A. Industria e Comercio (CSAN3):企業の財務・戦略的SWOT分析
    Cosan S.A. Industria e Comercio (CSAN3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Sanlam Kenya Plc:企業の戦略・SWOT・財務情報
    Sanlam Kenya Plc - Strategy, SWOT and Corporate Finance Report Summary Sanlam Kenya Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SAES Getters S.p.A. (SG):企業の財務・戦略的SWOT分析
    SAES Getters S.p.A. (SG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Lanco Infratech Ltd (LITL):企業の財務・戦略的SWOT分析
    Lanco Infratech Ltd (LITL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆